A review of 5:2 intermittent fasting, alternate day fasting or time restricted fasting for the management of obesity

PRASHANT PATEL, NAJEED KHAN, AHMED RASHID AHMED


DEPARTMENT OF SURGERY AND CANCER





BACKGROUND

- Nearly one quarter of UK adults are obese (BMI greater than 30g/m2)
- Prediction by 2050: 60% men, 50% women
- Leading cause of preventable death worldwide associated with a range of health problems including T2DM, CVD, Malignancy, OSA, OA
- Resulting NHS costs attributable to being obese are projected to reach £9.7 billion by 2050 with wide costs to society estimated to reach £49.9 billion per year
- Obesity it self is a pandemic!



TIER-3 WEIGHT MANAGEMENT SERVICES

- Very costly to deliver, £6 billion per year spent on obesity treatments & £10m for treating T2DM
- Tier-3 service provides minimally significant weight loss of 3-5%
- Poor adherence to diets with >50% weight regained in the first year following weight loss
- Introduction (but lacking of) Pharmacological agents e,g. Orlistat (lipase inhibitor), Saxenda, Wegovy
- Sustainable weight loss?
- What is the best diet strategy?



INTERMITTENT FASTING – A POSSIBLE SOLUTION?

- An umbrella term for a number of different strategies of fasting that do not involve a continuous restriction of calories daily
 - 1. 5:2 intermittent fasting
 - 2. Time-restricted feeding
 - 3. Alternate day fasting

Objectives:

Compare intermittent fasting strategies vs traditional continuous energy restriction (CER)

- Weight loss
- 2. Improving cardiometabolic factors




TIME RESTRICTED FEEDING

- Fasting and feeding at specific intervals within a 24-hour cycle. The most widely used and researched format of TRF is a 16-hour fast, with an 8-hour feeding window (16:8).
- Hypothesised to be effective for its affects on the human circadian rhythm



ALTERNATE DAY FASTING

- ADF restricts energy intake to every other day.
- This generally involves a feeding day, where food is consumed normally over a 24hour period, and a fasting day, where there is either partial or complete cessation of energy intake.



5:2 INTERMITTENT FASTING

- The 5:2 fasting method consists of 5 days of normal feeding days with 2 nonconsecutive or consecutive fasting days of minimal calorie intake
- Calories intake is commonly 0-25% of the estimated total energy requirements or average calorie consumption



METHODS



The databases PUBMED, EMBase, and Cochrane libraries were searched using the terms "intermittent fasting", "5:2 diet", "alternate day fasting", "alternate day feeding", "time restricted feeding", "time restricted fasting", "overweight", "obese".



Studies of adults (>18 y old) including RCT, single arm, and cohort studies, with overweight (BMI > 25) without additional co-morbidities participants were included for analysis.



27 studies met the inclusion criteria



RESULTS

- All three IF strategies; including ADF, TRF and 5:2, produced weight loss according to the standards set out in NICE guidelines, ranging from 2 − 10%, from baseline.
- Range of weight loss was achieved (P<0.05)
 - TRF: (2.6% 3.6%)
 - 5:2 IF (5.4% 6%)
 - ADF (3.2% 6.4%)
- Within the literature IF consistently outperformed a control group who were not given any intervention



Time restricted feeding 16:8

						Plasma Lipids			Gluoregula	atory markers		
Patients	Diet length	Design and intervention group	Body weight	Energy intake	Blood pressure	LDL	HDL	TG	Fasting glucose	Fasting insulin	Inflammation	Oxidative stress
N = 116	12 week	RCT, 2 groups 1) Control 2) TRF	0	NT	NT	0	0	0	0	0	NT	NT
N = 10	4 week	Single arm 1) TRF	↓2.2%	NT	0	NT	NT	NT	o	NT	NT	NT
N = 50 (ad 80%)	12 week	Single arm 1) TRF	↓2.5kg	NT	0	0	0	NT	NT	NT	NT	NT
N = 101	3 week	RCT, 3 groups 1) TRF 2) ADF (25%) 3) Control	1)↓2.7kg 2)↓4.9kg	NT	0	1) O 2) O	1) O 2) \(\psi 0.27	1) ↓0.34 2) O	1)O 2)↓0.13	NT	NT	NT
N = 20	12 week	RCT, 2 groups 1) TRF 2) Control	↓3.7%	↓EO 21.9%	0	0	0	0	0	o	NT	NT
N = 90 (ad 78%)	14 week	RCT, 2 groups 1) TRF 2) control (ER)	0	NT	↓6mmhg DBP	0	o	0	0	o	NT	NT
N = 90 ad 85%)	14 week	RCT, 2 groups 1) early TRF (+ER) 2) control (+ER)	↓2.3kg	0	↓4mmhg DBP	o	0	0	o	o	NT	NT
N = 46	12 week	Historical control trial 1) TRF 2) Control	↓2.6%	↓341kcal	↓7mmhg SBP	o	0	o	o	0	NT	NT

Table 1

Significant values mentioned in the table are when P<0.05 when compared to control or alternative intervention.

O = no significant change, NT = not tested, RCT = randomised controlled trial, ad = adherence, ADF = alternate day fasting, LDL = low density lipoproteins, HDL = high density lipoproteins, TG = triglycerides, TRF = time restricted feeding, ER = energy restriction, DBP = diastolic blood pressure, SBP = systolic blood pressure, EO = eating occasions

TRF

- Only 1 RCT showed statistically significant weight loss compared to CER.
- 2 RCT performed by Lowe et al. and Steger et al. showed no significant difference in bodyweight following a prolonged TRF period compared to a control group.
- 2 studies highlighted statistically significant reduction in energy intake compared to the controls
- 3 trials showed statistically significant reductions in blood pressure compared to controls



5:2 Intermittent					- 1	Plasma Lipids		pids	Glupregulatory markers			
Patients	Diet length	Design and intervention group	Body weight	Energy intake	Blood pressure	LDL	HDL	7G	Fasting glucose	Fasting insulin	Inflammation	Oxidative
N = 112	1 year	RCT, 2 groups 1) IF (400-600kcal fast) 2) CER	O Both ↓wt (IF 8-9kg)	0	o	0	0	0	0	0	0	0
N = 121 (ad 51%)	1 year	RCT, 2 groups 1) IF (500kcal fast) 2) CER	O Both \(\psi \text{(IF 3.2-4.8kg)} \)	NT	NT	NT	NT	NT	0	0	NT	NT
N = 34	16 week	RCT, 3 groups 1) IF (500-600kcal fast) 2) Normal intake + HIT 3) IF + HIT	1) 46%	0	0	0	0	0	0	0	NT	NT
N = 43	4 week	RCT, 2 groups 1) IF (600kcal fast) 2) CER	O Both ↓wt (IF 1.8-3kg)	0	0	0	0	0	2) ↓0.25	0	o	0
N = 24 (ad 73%)	24 week	RCT, 2 groups 1) IF (600kcal fast) 2) CER	O Both ↓wt (IF 5.2-5.5kg)	0	0	0	o	0	o	o	NT	NT.
N = 37	12 week	1) IF (25% ER fast) 2) CER	1) ↓5.9% 2) ↓2.3%	NT	NT	NT	NT	NT	NT	NT	NT	NT
N = 40	4 week	RCT 1) IF (0% fast) 2) Control	BMI ↓0.5	1)↓406kcal	NT	NT	NT	NT	NT	NT	NT	NT
N = 197 (ad 33%)	24 week	Cohort study, 2 groups 1) IF (~600kcal fast) 2) CER	1) ↓5.4% 2) ↓2.8%	o	1) SBP ↓7 2) SBP ↑6	0	o	o	o	0	NT	0
N = 107 (ad 58%)	24 week	RCT, 2 groups 1) IF (~600kcal fast) 2) CER	O Both J.wt (IF 6.4-5.6)	1)↓716ki	o	0	0	0	o	1)↓2.1 2)↓1.1	o	0
N = 150	24 week	RCT, 3 groups 1) IF (~25% ER fast) 2) CER 3) Control	1) ↓7% 2) ↓5% 3) O	1) ↓35% 2) ↓25% 3) O	0	0	0	0	0	o	0	NT

Table 2

Significant values mentioned in the table are when P<0.05 when compared to control or alternative intervention.

O = no significant change, NT = not tested, RCT = randomised controlled trial, ad = adherence, TRF = time restricted feeding, IF = intermittent fasting, CER = continuous energy restriction, ER = energy restriction, HIIT = high intensity interval training, BMI = Body mass index, LDL = low density lipoproteins, HDL = high density lipoproteins, TG = triglycerides, SBP = systolic blood pressure, \$\duse\$ wt = weight

5:2 IF

- All studies showed a significant weight loss from baseline
- Only 1 RCT showed statistically significant weight loss compared to CER,
- 5 studies showed no difference in the weight lost with 5:2 IF, compared to CER
- 2 studies showed reduced energy intake in 5:2 IF vs CER
- Where tested, 5:2 IF reduced lipid levels, with no significant difference to CER
- 1 study showed reduced fasting insulin levels, compared to the CER group.



	e day fasting								Glover	egulatory		
Patients	Diet length	Design and intervention group	Body weight	Energy Intake	Blood pressur e	Plasma Lipids				arkers		
						LDL	HDL	TG	Fasting glucose	Fasting Insulin	Inflammation	Oxidative stress
N =100 (ad 69%)	12 month	RCT, 3 groups 1) ADF (25%) 2) CER 3) control	0 (Both \$\psi \text{5-} 6%)	0	o	1) ↑ 1.2 2) ↓ 10.3	0	o	0	o	o	NT
N = 26 (ad 92%)	8 week	RCT, 2 groups 1) ADF (0%) 2) CER	0	1)↓47% 2)↓28%	NT	o	0	o	0	0	NT	NT
N = 74	8 week	RCT, 3 groups 1) ADF (25%) Lunch 2) ADF Dinner 3) ADF small meal	O All \$\psi_\psi_(3.5- 4.1kg)	0	0	0	0	0	0	0	NT	NT
N = 16	10 week	Single arm 1) ADF (25%)	↓5.7%	NT	NT	J34	0	↓48	NT	NT	NT	NT
N = 60 (ad 82%)	12 week	RCT, 4 groups 1) ADF (25%) 2) CER 3) Exercise 4) Control	1) 45.2kg 2) 45 kg 3) 45.1kg 4) 40.2kg *Not compared against each- other	NT.	NT	1)↓10 2)↓8	3)↑16	1)↓17	NT	NT	NT	NT
N = 101	3 week	RCT, 3 groups 1) TRF (600kcal) 2) ADF 3) Control	1)↓2.7kg 2)↓4.9kg	NT	NT	0	1) O 2) ↓0.27	1) ↓0.34 2) O	1)O 2)↓0.13	NT	NT	NT
N = 16	10 week	Single arm 1) ADF (25%)	↓5.6kg	NT	NT	↓ 25%	0	↓32%	NT	NT	NT	NT
N = 64	12 week	RCT, 4 groups 1) ADF (25%) + exercise 2) ADF 3) Exercise 4) Control	1)↓6kg 2)↓3kg 3)↓1kg 4) O	NT	0	NT	NT	NT	NT	NT	NT	NT
N = 42	24 week	RCT, 2 groups 1) ADF (25%) 2) Control	↓6.8kg	NT	NT	NT	NT	NT	0	↓4.5	o	NT

Significant values mentioned in the table are when P<0.05 when compared to control or alternative intervention. (Unless mentioned otherwise)

O = no significant change, NT = not tested, RCT = randomised controlled trial, ad = adherence, ADF 0% = alternate day fasting, ADF 25% = modified alternate day fasting, TRF = time restricted feeding, IF = intermittent fasting, CER = continuous energy restriction, ER = energy restriction, HIIT = high intensity interval training, BMI = Body mass index, LDL = low density lipoproteins, HDL = high density lipoproteins, TG = triglycerides, SBP = systolic blood pressure, ψ wt = weight reduction

ADF

- All studies showed a significant weight loss from baseline.
- No studies showed statistically significant weight loss compared to CER
- Only I RCT comparing 2 different IF protocols, showed ADF was superior to TRF in producing weight loss.
- ADF consistently reduced SPB in studies, however this was not statistically significant compared to CER or exercise
- ADF reduced both LDL and TG levels, with I RCT showing ADF was superior to CER or exercise.



DISCUSSION

- ADF, 5:2 IF and TRF all show modest weight loss results
- Lack of consistent results
- Little evidence to suggest any IF strategy is superior to traditional methods of dieting such as CER
- Safe and feasible alternative to calorie restriction diets and could provide structure and routine for patients
- A 3-arm comparative clinical trial is required to see if any one protocol delivers clinically significant superior results.



Questions?